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BACKGROUND: To evaluate the prognostic value of lymph node density (LND) in patients with lymph node-positive cervical cancer.
METHODS: A total of 88 consecutive patients were included in our study. Patients were treated with cisplatin-based concomitant
chemoradiotherapy after surgical staging was performed at the Medical University of Vienna. Lymph node density, that is, the ratio of
positive lymph nodes to the total number of lymph nodes removed, was assessed pathologically. Patients were stratified into two
groups according to LND: patients with LND p10% and patients with LND 410%. Lymph node density was correlated with
clinicopathological parameters by w
2-tests. Univariate log-rank tests and multivariate Cox regression models were used to evaluate
the association between LND and survival.
RESULTS: A significant correlation between LND and FIGO stage (P¼0.03), but not patients’ age (P¼0.2), histological grade (P¼0.8),
and histological type (P¼0.5), was observed. In a univariate survival analysis, LND (P¼0.01; P¼0.01), FIGO stage (P¼0.01;
P¼0.008), and histological grade (P¼0.03; P¼0.04) were associated with disease-free and overall survival, respectively. Patients
with LND 410% had impaired disease-free and overall survival rates compared with patients with LND p10%. In a multivariate
regression model, LND (P¼0.01; Po0.05) and FIGO stage (P¼0.002; P¼0.002) were independent predictors of disease-free and
overall survival, respectively.
CONCLUSIONS: LND 410% is associated with an impaired disease-free and overall survival. Lymph node density may be used as an
independent prognostic parameter in patients with lymph node-positive cervical cancer.
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Lymph node involvement is the most important prognostic
parameter for patients with cervical cancer (Committee on Practice
Bulletins-Gynecology, 2002; Tseng et al, 2010). The presence of lymph
node metastases significantly influences patient’s outcome and
therapeutic modalities more than any other clinical or pathological
feature. Moreover, it has been shown that the number of involved
lymph nodes has a proportionately adverse influence on the
prognosis of patients who have undergone surgery (Tanaka et al,
1984). Patients with locally advanced cervical cancer and lymph node
involvement are best treated with primary radiotherapy (external
beam plus brachytherapy) and concomitant chemotherapy. It has
been shown that concomitant chemotherapy improves 5-year survival
rates by 30–50 percent compared with radiotherapy alone (Commit-
tee on Practice Bulletins-Gynecology, 2002; Green et al, 2005).
Several recent studies have focused on the clinical relevance of
lymph node density (LND) in assessing cancer prognosis
(Herr, 2003; Chan et al, 2007; Ooki et al, 2007; Kassouf et al,
2008; Yamashita et al, 2008; Cai et al, 2009; Gil et al, 2009; Svatek
et al, 2009; Vinh-Hung et al, 2009). In these studies, LND was
defined as the ratio of the number of metastatic lymph nodes and
the total number of lymph nodes removed. Thus, this parameter
incorporates not only the burden of nodal disease and cancer
spread but also the extent of nodal dissection and surgical staging.
To date, no study has assessed the prognostic value of LND in
patients with cervical cancer.
The purpose of this study was to evaluate the role of LND in the
prognosis of patients with lymph node-positive cervical cancer.
MATERIALS AND METHODS
Patients
Institutional review board approval for this study was obtained
from the Ethics Committee of the Medical University of Vienna
(IRB approval number: 246-2009). A total of 88 patients with
invasive, nodal-positive cancer of the uterine cervix underwent
systemic surgical lymph node staging and were enrolled in the
present study. Patients were treated at the Department of
Obstetrics and Gynecology, Division of Gynecologic Oncology,
Medical University of Vienna, Austria between January 1995 and
December 2008. Patients’ clinical and survival data were extracted
from an electronic database, retrospectively.
Clinical management
Patients with invasive nodal-positive cervical cancer (FIGO
IB1–IVA) were treated with chemoradiotherapy, after systemic
surgical lymph node staging was performed, as described previously
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s(Polterauer et al, 2008). Chemoradiotherapy was conducted,
using weekly cisplatin (40mgm
 2) and concurrent external-beam
radiation therapy to the whole pelvic area (with an aim of 80–85Gy)
with a four-field technique, followed up by intracavitary brachy-
therapy (50–55Gy). Tissue samples obtained from staging opera-
tions were sent to the department of pathology for histological
examination. Board-approved pathologists, specialised in gynaeco-
logical pathology, assessed the pathological specimens. Formalin-
fixed samples from each defined topographical localisation were
described macroscopically for size, consistency, and number of
lymph nodes. Individual recognisable lymph nodes were divided
and paraffin embedded. To guarantee detection of all the nodes,
even small nodes, remaining fatty tissue was also embedded.
Finally, paraffin blocks were serially sectioned and stained with
haematoxylin and eosin for microscopical examination. The number
and location of total resected and metastatically involved pelvic and
paraaortic lymph nodes was assessed.
After completion of concurrent chemoradiotherapy, patients
were scheduled for the first follow-up visit 3 months after
completion of therapy. For the next 3 years, patients were followed
up every 3 months, in the fourth and fifth year bi-annually, and
yearly from the sixth to the tenth year after primary therapy. If
patients did not present at scheduled follow-up visits, they were
contacted by administrative personnel. If any clinically suspicious
finding and/or tumour marker elevation was detected, computed
tomography was performed. Following international guidelines,
recurrent disease was either diagnosed clinically, by biopsy, or by
imaging methods. Patient with recurrent disease were either
treated with single- or multidrug chemotherapy or with surgery.
Documentation of death and causes of death was performed using
post-mortem inspection or autopsy results.
Statistical analysis
Values are given as mean (standard deviation) or median
(inter-quartile range). The w
2-tests were used to compare LND
and clinicopathological parameters. Patients were stratified into
two risk groups according to LND (o10% vs X10%). The cutoff
value was chosen based on preliminary data (Ooki et al, 2007).
Lymph node density was correlated with FIGO stage (I vs II vs III
vs IV), patients’ age (o50 vs X50 years), histological grade (G1 vs
G2 vs G3), and histological type (squamous cell vs adeno- and
adenosquamous carcinoma).
Univariate survival probabilities were calculated by the
product limit method of Kaplan and Meier. Differences between
groups were tested using the log-rank test. Multivariate Cox
proportional hazard models for disease-free and overall survival
were performed. The results were analysed for the end point of
disease-free and overall survival. Survival time periods of patients
who are disease-free or still alive or dead as a result of other causes
were censored with the last follow-up date. Univariate sub-group
analyses according to FIGO stage were performed subsequently.
The P-values of o0.05 were considered statistically significant.
We used the statistical software SPSS 16.0 for Windows (SPSS 16.0,
SPSS Inc, Chicago, IL, USA) for statistical analysis.
RESULTS
Mean age of patients at diagnosis was 49. 9 (14.1) years. Of the
88 patients, 86 (98%) and 2 (2%) patients had pelvic and paraaortic
lymph node involvement, respectively. A mean/median number of
20.3 (11.6)/18.5 (12–27) and 3.1 (3.8)/2.0 (1–3) lymph nodes was
resected or involved, respectively. A total of 36 (41%) and 52 (59%)
patients were assigned to the LND group p10% and 410%,
respectively. Mean/median follow-up time for this cohort of
patients was 37.1 (28.0)/34.5 (14–57) months. Patients’ charac-
teristics are given in Table 1.
In Table 2, we present the results of the association of LND
and clinicopathological parameters. A significant association
between LND groups and FIGO stage (P¼0.03), but not patients’
age (P¼0.2), histological grade (P¼0.8), and histological type
(P¼0.5), was observed.
In univariate survival analysis, LND (P¼0.01; P¼0.01), FIGO
stage (P¼0.01; P¼0.008), and histological grade (P¼0.03;
P¼0.04) were associated with disease-free and overall survival.
Kaplan–Meier curves according to LND groups and disease-free
and overall survival are shown in Figures 1 and 2, respectively.
Patients of the LND p10% group compared with the LND 410%
group had 5-year overall survival rates of 67 and 38%, respectively.
In multivariate survival analysis, only LND (P¼0.01; Po0.05) and
FIGO stage (P¼0.002; P¼0.002) were associated with disease-free
and overall survival, respectively. Patients with LND 410%
showed impaired disease-free and overall survival compared with
patients with LND p10%. Results of the univariate and multi-
variate survival analyses are provided in Table 3. A univariate sub-
group survival analysis according to FIGO stages showed that LND
was associated with overall survival in patients with FIGO stage I
(P¼0.01), but not with stage II (P¼0.7), III (P¼0.8), and IV
(P¼0.3). In a multivariate analysis, LND was not associated with
survival in patients with FIGO stage I (P¼0.9).
DISCUSSION
We investigated the prognostic value of LND for survival in
patients with lymph node-positive cancer of the uterine cervix.
Table 1 Patients’ characteristics
Parameter N or mean (s.d.)
Total number of patients enrolled 88
Age at diagnosis (years) 49.9 (14.1)
Histological type
Squamous cell carcinoma 71 (80.7%)
Adenocarcinoma 12 (13.6%)
Adenosquamous carcinoma 5 (5.7%)
Tumour stage
FIGO IB1 20 (22.7%)
FIGO IB2 10 (11.4%)
FIGO IIA 7 (8.0%)
FIGO IIB 38 (43.2%)
FIGO IIIA 2 (2.3%)
FIGO IIIB 9 (10.2%)
FIGO IVA 2 (2.2%)
Parametrial involvement
Negative 39 (44.3%)
Positive 49 (55.7%)
Histological grade
G1 7 (8.0%)
G2 49 (55.7%)
G3 32 (36.3%)
Recurrence status
No. of patients with recurrent disease 40 (45.5%)
Mean time to recurrent disease (months) 18.9 (16.9)
Status at last observation
Alive with no evidence of disease or stable disease 46 (52.3%)
Progressive disease 4 (4.5%)
Tumour-related death 34 (38.6%)
Dead as a result of other causes 4 (4.5%)
Abbreviations: FIGO¼International Federation of Gynecologists and Obstetricians;
s.d.¼standard deviation.
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and overall survival.
Nodal metastases at the time of initial evaluation in patients with
cervical cancer portend an impaired prognosis. The 5-year survival
rates of women with stage IB cervical cancer with and without
lymph node metastasis are 73.1 and 87.7%, respectively. Women
with stage IIA cervical cancer with and without lymph node
metastasis have 5-year survival rates of 40.9 and 79.8%,
respectively (Lee et al, 1989). Owing to its powerful predictive
ability, the incorporation of nodal status into clinical cervical
staging has been discussed (Committee on Practice Bulletins-
Gynecology, 2002). A number of studies have observed that
location and extent of positive lymph nodes are important
determinants in patients with cervical cancer (Tanaka et al, 1984;
Lai et al, 2003; Singh and Arif, 2004). Decreased disease-free and
overall survival rates have been reported in patients with an
increasing number of positive lymph nodes and in patients with
paraaortic lymph node metastases (Delgado et al, 1990).
We observed that patients with a higher LND had impaired
disease-free and overall survival rates. In multivariate survival
analyses, only FIGO stage and LND remained independent
predictors of survival. A considerable number of our patients
(36/88 (41%)) had LND p10%. Of note, the 5-year overall survival
rates of these patients are comparable with patients with FIGO
stage IIA without lymph node involvement (Singh et al, 2004).
These findings are novel and may assist the physician to better
define prognosis and more importantly, stratify patients into
various risk groups in the design of future clinical trials.
Furthermore, our results can be helpful for patient counselling
as patients with LND p10% seem to have similar prognosis as
patients with locally advanced disease without lymph node
metastases. One might argue that the good prognosis in LND
p10% could be caused by the low number of positive lymph
nodes in this group. To show prognostic superiority of LND to the
number of positive lymph nodes, we performed a survival analysis
regarding the number of positive lymph nodes (1 vs 2 vs 42).
In our data set, this parameter was not significantly associated
with overall survival (P¼0.08).
Sub-group analysis was performed to characterise the additional
prognostic benefit of LND in patients within the same tumour
stage. Lymph node density 410% was associated with impaired
overall survival in a univariate sub-group analysis for patients with
FIGO stage I. In a multivariate model, we could not confirm these
findings. This might be related to the relatively small number of
patients (n¼30) and deaths (n¼6) in this sub-group.
In our study group, the median number of resected nodes
was relatively high (18.5 (12–27)). According to the Gynecologic
Oncology Group Surgical Procedures Manual (revised in 2005,
www.gog.org), an adequate lymph node dissection requires that a
minimum of four lymph nodes be shown pathologically from each
side (right and left) of the pelvis, preferably from multiple sites.
Our results are in accordance with findings in other malig-
nancies. A prognostic value of LND has been shown for several
solid tumours, such as endometrial, breast, bladder, renal,
prostate, oesophageal, gastric, oral, and penile cancer (Herr,
2003; Chan et al, 2007; Ooki et al, 2007; Kassouf et al, 2008;
Yamashita et al, 2008; Cai et al, 2009; Gil et al, 2009; Svatek et al,
Table 2 Relationship between clinicopathological parameters and lymph
node density in 88 patients with lymph node-positive cervical cancer
LND p10%
(n¼36)
LND 410%
(n¼52) P-value
a
Tumour stage 0.03
FIGO I 18/30 (60.0%) 12/30 (40.0%)
FIGO II 13/45 (28.8%) 32/45 (71.2%)
FIGO III and IV 5/13 (38.5%) 8/13 (31.5%)
Age at first diagnosis 0.2
o50 years 22/48 (45.8%) 26/48 (54.2%)
X50 years 14/40 (35.0%) 36/52 (65.0%)
Histological grade 0.8
G1 2/6 (33.3%) 4/6 (66.7%)
G2 20/46 (43.5%) 26/46 (56.5%)
G3 11/30 (36.7%) 19/30 (63.3%)
Histological type 0.5
Squamous cell carcinoma 28/71 (39.4%) 43/71 (60.6%)
Adenosquamous carcinoma 7/16 (43.8%) 9/16 (56.2%)
Abbreviations: FIGO¼International Federation of Gynecologists and Obstetricians;
LND¼lymph node density.
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Figure 1 Kaplan–Meier curves for disease-free survival in patients with
cervical cancer broken down by lymph node density.
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Figure 2 Kaplan–Meier curves for overall survival in patients with
cervical cancer broken down by lymph node density.
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has been shown to be a more important predictor for prognosis
than tumour stage or lymph node involvement (Kassouf et al,
2008). Lymph node density has been shown to provide more
accurate prognostic information than the total number of positive
nodes (Vinh-Hung et al, 2009), and its incorporation in a
novel staging system has been suggested. A change in surgical
staging would have clinical implications on treatment planning
and follow-up.
Of note, a shortcoming of our study is the limited number of
patients and the retrospective design. Furthermore, the treatment
period of 13 years is relatively long.
We showed that LND is an independent prognostic parameter
in patients with lymph node-positive cervical cancer and that it
can be considered as a useful clinical tool, allowing classification
into prognostic sub-groups. We believe that LND adds important
information not only related to disease burden but also to staging
quality. Lymph node density is influenced by surgical technique,
anatomic circumstances and the quality and accuracy of the
pathological analysis, reflecting an objective parameter in the
assessment of the procedure’s extent and completeness. For the
subset of patients with favourable prognosis (that is, LND p10%)
regular follow-up may be a suitable choice, whereas patients with
an unfavourable prognosis (that is, LND 410%) might possibly
benefit from consolidation chemotherapy or another novel
adjuvant treatment modality after chemoradiotherapy. However,
these novel findings need to be validated in a larger, prospective,
independent data set.
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